银屑病患者非酒精性脂肪性肝病:全身炎症负荷的后果?
综述探讨银屑病患者非酒精性脂肪性肝病(NAFLD)风险增高的病理生理机制,认为慢性低度炎症可能起关键作用。促炎脂肪因子和肝因子升高、抗炎脂联素降低导致胰岛素抵抗,多步骤促进NAFLD发生发展。建议所有银屑病患者考虑NAFLD筛查,并推测生物制剂可能通过减轻全身炎症延缓NAFLD进展。
要点
- 银屑病患者NAFLD风险高于一般人群,应视为筛查候选人群。
- 慢性低度炎症失衡(促炎因子升高、脂联素降低)可能介导胰岛素抵抗与NAFLD进展。
- 生物制剂可能通过抑制全身炎症而延缓NAFLD进展,但需进一步验证。
核心结论
- 银屑病患者NAFLD风险增加,慢性低度炎症可能是其共同病理生理基础。
- 所有银屑病患者均应考虑NAFLD筛查并据此管理。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 银屑病与NAFLD均与促炎脂肪因子(如肿瘤坏死因子-α、白细胞介素-6)和肝因子水平升高相关。
- 两种疾病均与抗炎脂肪因子脂联素水平降低相关。
- 炎症介质失衡可导致胰岛素抵抗,从而以多步骤方式促进NAFLD发生和进展。
临床怎么用
- 将所有银屑病患者视为NAFLD筛查候选人群并进行相应管理。
- 生物制剂对银屑病NAFLD进展的潜在作用尚属假设,需临床研究验证。
局限性
- 本文为综述,未提供原始研究数据或系统检索策略。
- 生物制剂延缓NAFLD进展的推测缺乏直接临床证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with psoriasis are at an increased risk for nonalcoholic fatty liver disease (NAFLD) compared with the general population. However, the pathophysiology underlying this comorbidity and elucidation of effective treatment strategies are unclear. This review provides insights into the possible role of chronic, low-grade inflammation in the pathogenesis of NAFLD in patients with psoriasis. Both conditions are associated with increased levels of proinflammatory adipokines (such as tumour necrosis factor-α and interleukin-6) and hepatokines, and decreased levels of adiponectin, an anti-inflammatory adipokine. This imbalance in inflammatory mediators could result in insulin resistance and, thereby, facilitate the occurrence and progression of NAFLD in a multistep manner. All patients with psoriasis should, therefore, be considered candidates for NAFLD screening and managed accordingly. Given the common aetiology of inflammation between these conditions, it is hypothesized that biological therapies for psoriasis may attenuate the systemic inflammatory process and progression of NAFLD in patients with psoriasis.
引用
- Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol. 2018. PMID: 29235656. doi:10.1111/bjd.16239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。